

Doris Hendig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4148565/publications.pdf>

Version: 2024-02-01

66
papers

1,440
citations

257450

24
h-index

377865

34
g-index

66
all docs

66
docs citations

66
times ranked

1317
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary affection of patients with Pseudoxanthoma elasticum: Long-term development and genotype-phenotype-correlation. <i>Intractable and Rare Diseases Research</i> , 2022, 11, 7-14.	0.9	1
2	The Impact of Inflammatory Stimuli on Xylosyltransferase-I Regulation in Primary Human Dermal Fibroblasts. <i>Biomedicines</i> , 2022, 10, 1451.	3.2	3
3	Statins as a Therapeutic Approach for the Treatment of Pseudoxanthoma Elasticum Patients: Evaluation of the Spectrum Efficacy of Atorvastatin In Vitro. <i>Cells</i> , 2021, 10, 442.	4.1	3
4	Cytokine-mediated induction of human xylosyltransferase-I in systemic sclerosis skin fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 2021, 549, 34-39.	2.1	6
5	Development of a xylosyltransferase-I-selective UPLC MS/MS activity assay using a specific acceptor peptide. <i>Biochimie</i> , 2021, 184, 88-94.	2.6	5
6	Evidence of Long-Lasting Humoral and Cellular Immunity against SARS-CoV-2 Even in Elderly COVID-19 Convalescents Showing a Mild to Moderate Disease Progression. <i>Life</i> , 2021, 11, 805.	2.4	7
7	Genetic deletion of <i>Abcc6</i> disturbs cholesterol homeostasis in mice. <i>Scientific Reports</i> , 2021, 11, 2137.	3.3	11
8	Retinal findings in carriers of monoallelic <i>ABCC6</i> mutations. <i>British Journal of Ophthalmology</i> , 2020, 104, 1089-1092.	3.9	5
9	Xylosyltransferase-deficient human HEK293 cells show a strongly reduced proliferation capacity and viability. <i>Biochemical and Biophysical Research Communications</i> , 2020, 521, 507-513.	2.1	4
10	Cellular and Molecular Biomarkers Indicate Premature Aging in Pseudoxanthoma Elasticum Patients. , 2020, 11, 536.		12
11	IMPAIRED DARK ADAPTATION ASSOCIATED WITH A DISEASED BRUCH MEMBRANE IN PSEUDOXANTHOMA ELASTICUM. <i>Retina</i> , 2020, 40, 1988-1995.	1.7	24
12	Identification of Putative Non-Substrate-Based XT-I Inhibitors by Natural Product Library Screening. <i>Biomolecules</i> , 2020, 10, 1467.	4.0	8
13	Linking <i>ABCC6</i> Deficiency in Primary Human Dermal Fibroblasts of PXE Patients to p21-Mediated Premature Cellular Senescence and the Development of a Proinflammatory Secretory Phenotype. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9665.	4.1	11
14	microRNA-145 mediates xylosyltransferase-I induction in myofibroblasts via suppression of transcription factor KLF4. <i>Biochemical and Biophysical Research Communications</i> , 2020, 523, 1001-1006.	2.1	10
15	Activin A-Mediated Regulation of XT-I in Human Skin Fibroblasts. <i>Biomolecules</i> , 2020, 10, 609.	4.0	6
16	Acute Retinopathy in Pseudoxanthoma Elasticum. <i>JAMA Ophthalmology</i> , 2019, 137, 1165.	2.5	29
17	<i>Abcc6</i> deficiency in mice leads to altered ABC transporter gene expression in metabolic active tissues. <i>Lipids in Health and Disease</i> , 2019, 18, 2.	3.0	9
18	First description of a compensatory xylosyltransferase I induction observed after an antifibrotic UDP-treatment of normal human dermal fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 2019, 512, 7-13.	2.1	4

#	ARTICLE	IF	CITATIONS
19	Retinal imaging including optical coherence tomography angiography for detecting active choroidal neovascularization in pseudoxanthoma elasticum. <i>Clinical and Experimental Ophthalmology</i> , 2019, 47, 240-249.	2.6	11
20	Carotid strain measurement in patients with pseudoxanthoma elasticum – Hint for a different pathomechanism?. <i>Intractable and Rare Diseases Research</i> , 2018, 7, 25-31.	0.9	5
21	microRNA-29b mediates fibrotic induction of human xylosyltransferase-I in human dermal fibroblasts via the Sp1 pathway. <i>Scientific Reports</i> , 2018, 8, 17779.	3.3	14
22	Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays. <i>Clinica Chimica Acta</i> , 2018, 486, 347-356.	1.1	27
23	Characterization of dermal myofibroblast differentiation in pseudoxanthoma elasticum. <i>Experimental Cell Research</i> , 2017, 360, 153-162.	2.6	11
24	Ageing affects chondroitin sulfates and their synthetic enzymes in the intervertebral disc. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, 17049.	17.1	37
25	Quantitative Fundus Autofluorescence in Pseudoxanthoma Elasticum. , 2017, 58, 6159.		24
26	Increased vascular occlusion in patients with pseudoxanthoma elasticum. <i>Vasa - European Journal of Vascular Medicine</i> , 2017, 46, 47-52.	1.4	14
27	Frequency, Phenotypic Characteristics and Progression of Atrophy Associated With a Diseased Bruch's Membrane in Pseudoxanthoma Elasticum. , 2016, 57, 3323.		55
28	Copy number variation in the <i>ATP-binding cassette transporter ABCC6</i> gene and <i>ABCC6</i> pseudogenes in patients with pseudoxanthoma elasticum. <i>Molecular Genetics & Genomic Medicine</i> , 2015, 3, 233-237.	1.2	6
29	UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays. <i>PLoS ONE</i> , 2015, 10, e0145478.	2.5	35
30	Reticular Pseudodrusen Associated With a Diseased Bruch Membrane in Pseudoxanthoma Elasticum. <i>JAMA Ophthalmology</i> , 2015, 133, 581.	2.5	56
31	Human xylosyltransferases – mediators of arthrofibrosis? New pathomechanistic insights into arthrofibrotic remodeling after knee replacement therapy. <i>Scientific Reports</i> , 2015, 5, 12537.	3.3	34
32	Identification and characterization of human xylosyltransferase II promoter single nucleotide variants. <i>Biochemical and Biophysical Research Communications</i> , 2015, 458, 901-907.	2.1	0
33	Xylosyltransferase II is the predominant isoenzyme which is responsible for the steady-state level of xylosyltransferase activity in human serum. <i>Biochemical and Biophysical Research Communications</i> , 2015, 459, 469-474.	2.1	14
34	First description of the complete human xylosyltransferase-I promoter region. <i>BMC Genetics</i> , 2014, 15, 129.	2.7	10
35	Choroidal Changes Associated With Bruch Membrane Pathology in Pseudoxanthoma Elasticum. <i>American Journal of Ophthalmology</i> , 2014, 158, 198-207.e3.	3.3	37
36	ABCC6- a new player in cellular cholesterol and lipoprotein metabolism?. <i>Lipids in Health and Disease</i> , 2014, 13, 118.	3.0	29

#	ARTICLE	IF	CITATIONS
37	Variants in genes encoding pyrophosphate metabolizing enzymes are associated with Pseudoxanthoma elasticum. <i>Clinical Biochemistry</i> , 2014, 47, 60-67.	1.9	12
38	Measurement of HMG CoA reductase activity in different human cell lines by ultra-performance liquid chromatography tandem mass spectrometry. <i>Biochemical and Biophysical Research Communications</i> , 2014, 443, 641-645.	2.1	2
39	Pyrophosphates as a major inhibitor of matrix calcification in Pseudoxanthoma elasticum. <i>Journal of Dermatological Science</i> , 2014, 75, 109-120.	1.9	33
40	Large-Scaled Metabolic Profiling of Human Dermal Fibroblasts Derived from Pseudoxanthoma Elasticum Patients and Healthy Controls. <i>PLoS ONE</i> , 2014, 9, e108336.	2.5	26
41	Human xylosyltransferase-I "A new marker for myofibroblast differentiation in skin fibrosis. <i>Biochemical and Biophysical Research Communications</i> , 2013, 436, 449-454.	2.1	36
42	Weiterbildung in der Klinischen Chemie und Laboratoriumsmedizin in Europa. <i>Laboratoriums Medizin</i> , 2013, 37, 275-285.	0.6	0
43	New insights into the pathogenesis of pseudoxanthoma elasticum and related soft tissue calcification disorders by identifying genetic interactions and modifiers. <i>Frontiers in Genetics</i> , 2013, 4, 114.	2.3	21
44	Fast and sample cleanup-free measurement of nicotine and cotinine by stable isotope dilution ultra-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 67-68, 137-143.	2.8	14
45	Transglutaminase 2 regulates early chondrogenesis and glycosaminoglycan synthesis. <i>Mechanisms of Development</i> , 2011, 128, 234-245.	1.7	23
46	Monthly Ranibizumab for Choroidal Neovascularizations Secondary to Angioid Streaks in Pseudoxanthoma Elasticum: A One-Year Prospective Study. <i>American Journal of Ophthalmology</i> , 2011, 152, 695-703.	3.3	46
47	Analysis of MMP2 promoter polymorphisms in patients with pseudoxanthoma elasticum. <i>Clinica Chimica Acta</i> , 2010, 411, 1487-1490.	1.1	14
48	Centrifugal Fundus Abnormalities in Pseudoxanthoma Elasticum. <i>Ophthalmology</i> , 2010, 117, 1406-1414.	5.2	64
49	Vascular endothelial growth factor gene polymorphisms as prognostic markers for ocular manifestations in pseudoxanthoma elasticum. <i>Human Molecular Genetics</i> , 2009, 18, 3344-3351.	2.9	36
50	Characterization of the ATP-binding cassette transporter gene expression profile in Y79: a retinoblastoma cell line. <i>Molecular and Cellular Biochemistry</i> , 2009, 328, 85-92.	3.1	26
51	Elevated circulating levels of matrix metalloproteinases MMP-2 and MMP-9 in pseudoxanthoma elasticum patients. <i>Journal of Molecular Medicine</i> , 2009, 87, 965-970.	3.9	23
52	The local calcification inhibitor matrix Gla protein in pseudoxanthoma elasticum. <i>Clinical Biochemistry</i> , 2008, 41, 407-412.	1.9	34
53	Gene expression profiling of ABC transporters in dermal fibroblasts of pseudoxanthoma elasticum patients identifies new candidates involved in PXE pathogenesis. <i>Laboratory Investigation</i> , 2008, 88, 1303-1315.	3.7	37
54	Elevated serum levels of intercellular adhesion molecule ICAM-1 in Pseudoxanthoma elasticum. <i>Clinica Chimica Acta</i> , 2008, 394, 54-58.	1.1	5

#	ARTICLE	IF	CITATIONS
55	Identification of a xylosyltransferase II gene haplotype marker for diabetic nephropathy in type 1 diabetes. <i>Clinica Chimica Acta</i> , 2008, 398, 90-94.	1.1	14
56	Complement Factor H Variant p.Y402H in Pseudoxanthoma Elasticum Patients. <i>Genetic Testing and Molecular Biomarkers</i> , 2008, 12, 431-436.	1.7	2
57	Pseudoxanthoma Elasticum: Genetic Variations in Antioxidant Genes Are Risk Factors for Early Disease Onset. <i>Clinical Chemistry</i> , 2007, 53, 1734-1740.	3.2	57
58	SPP1 Promoter Polymorphisms: Identification of the First Modifier Gene for Pseudoxanthoma Elasticum. <i>Clinical Chemistry</i> , 2007, 53, 829-836.	3.2	56
59	Mutational analysis of the ABCC6 gene and the proximal ABCC6 gene promoter in German patients with pseudoxanthoma elasticum (PXE). <i>Human Mutation</i> , 2006, 27, 831-831.	2.5	55
60	Role of Serum Fetuin-A, a Major Inhibitor of Systemic Calcification, in Pseudoxanthoma Elasticum. <i>Clinical Chemistry</i> , 2006, 52, 227-234.	3.2	80
61	New ABCC6 gene mutations in German pseudoxanthoma elasticum patients. <i>Journal of Molecular Medicine</i> , 2005, 83, 140-147.	3.9	30
62	Elevated xylosyltransferase I activities in pseudoxanthoma elasticum (PXE) patients as a marker of stimulated proteoglycan biosynthesis. <i>Journal of Molecular Medicine</i> , 2005, 83, 984-992.	3.9	37
63	Novel Mutations in the ABC6 Gene of German Patients with Pseudoxanthoma Elasticum. <i>Human Biology</i> , 2005, 77, 367-384.	0.2	23
64	Analysis of Sequence Variations in the <i>ABCC6</i> Gene among Patients with Abdominal Aortic Aneurysm and Pseudoxanthoma Elasticum. <i>Journal of Vascular Research</i> , 2005, 42, 424-432.	1.4	21
65	Assessment of a rapid-cycle PCR assay for the identification of the recurrent c.3421C>T mutation in the ABCC6 gene in pseudoxanthoma elasticum patients. <i>Laboratory Investigation</i> , 2004, 84, 122-130.	3.7	25
66	Assessment of a rapid-cycle PCR assay for the identification of the recurrent c.3421C>T mutation in the ABCC6 gene in pseudoxanthoma elasticum patients. <i>Laboratory Investigation</i> , 2004, 84, 122-130.	3.7	11